Funding outcome

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder causing children's muscles and connective tissues to turn into bone, severely limiting their movement. This life-changing condition occurs due to a mistake in a specific gene, leading to unwanted bone growth. Current treatments, such as a drug called palovarotene, have significant limitations, particularly for young patients. They cannot distinguish between normal and mutated gene functions, leading to adverse effects and inadequate treatment response. Our research introduces a novel approach: using artificial DNA-like molecules. These molecules are designed to target and correct the specific gene mutation causing FOP. We plan to test this method in an FOP mouse model, closely mimicking the human condition. The study involves giving multiple injections of DNA-like molecules to observe their impact on the symptoms and overall health of these mice. We expect to see their symptoms improve and they live longer. We anticipate this research to provide crucial insights into the effectiveness of ASOs in treating FOP. Our goal is to develop a treatment that is not only more effective but also safer for children, focusing on reducing unwanted bone growth without harmful side effects. This could significantly improve the quality of life for young FOP patients, offering a beacon of hope where options are currently limited. Our study also aims to understand the broader implications of using DNA-like molecules in genetic disorders. Successful results could pave the way for innovative treatments for other similar conditions, marking a significant advancement in genetic medicine and care for children.